The stock of Enlivex Therapeutics Ltd (ENLV) has seen a -5.22% decrease in the past week, with a 2.83% gain in the past month, and a -14.84% decrease in the past quarter. The volatility ratio for the week is 11.79%, and the volatility levels for the past 30 days are at 10.06% for ENLV. The simple moving average for the past 20 days is 0.98% for ENLV’s stock, with a -15.02% simple moving average for the past 200 days.
Is It Worth Investing in Enlivex Therapeutics Ltd (NASDAQ: ENLV) Right Now?
Moreover, the 36-month beta value for ENLV is 0.75. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ENLV is 19.34M and currently, short sellers hold a 0.59% of that float. On March 14, 2025, ENLV’s average trading volume was 137.81K shares.
ENLV) stock’s latest price update
Enlivex Therapeutics Ltd (NASDAQ: ENLV)’s stock price has gone decline by -9.17 in comparison to its previous close of 1.20, however, the company has experienced a -5.22% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-03-04 that Ness-Ziona, Israel, March 04, 2025 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a live investor webinar on March 5, 2025, at 11:00 a.m. ET to discuss the positive interim six-month data from the Phase I stage of its ongoing randomized, multi-country Phase I/II Allocetra™ trial in patients with moderate to severe knee osteoarthritis.
Analysts’ Opinion of ENLV
Many brokerage firms have already submitted their reports for ENLV stocks, with H.C. Wainwright repeating the rating for ENLV by listing it as a “Buy.” The predicted price for ENLV in the upcoming period, according to H.C. Wainwright is $33 based on the research report published on March 02, 2021 of the previous year 2021.
ENLV Trading at -2.44% from the 50-Day Moving Average
After a stumble in the market that brought ENLV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.25% of loss for the given period.
Volatility was left at 10.06%, however, over the last 30 days, the volatility rate increased by 11.79%, as shares surge +3.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.40% lower at present.
During the last 5 trading sessions, ENLV fell by -5.22%, which changed the moving average for the period of 200-days by -20.42% in comparison to the 20-day moving average, which settled at $1.0794. In addition, Enlivex Therapeutics Ltd saw -6.84% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENLV
The total capital return value is set at -0.6. Equity return is now at value -57.93, with -49.35 for asset returns.
Based on Enlivex Therapeutics Ltd (ENLV), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -18.24.
Currently, EBITDA for the company is -28.22 million with net debt to EBITDA at 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.71.
Conclusion
To wrap up, the performance of Enlivex Therapeutics Ltd (ENLV) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
